Loading...
Cadila Pharmaceuticals Limited — Erythromycin Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #6 for Erythromycin · $1.4M export value · DGFT Verified
Cadila Pharmaceuticals Limited is the #6 Indian exporter of Erythromycin with $1.4M in export value and 69 verified shipments. Cadila Pharmaceuticals Limited holds a 1.8% market share in Erythromycin exports across 5 countries. The company exports 15 pharmaceutical products worth $20.2M across 11 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $1.2M | 58 | 91.5% |
| FRANCE | $47.6K | 5 | 3.5% |
| ZIMBABWE | $44.2K | 4 | 3.3% |
| BELGIUM | $11.9K | 1 | 0.9% |
| JAMAICA | $10.5K | 2 | 0.8% |
Cadila Pharmaceuticals Limited exports Erythromycin to 5 countries. The largest destination is UNITED STATES accounting for 91.5% of Cadila Pharmaceuticals Limited's Erythromycin shipments, followed by FRANCE (3.5%) and ZIMBABWE (3.3%). These destinations reflect Cadila Pharmaceuticals Limited's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| LIFESCIENCE LOGISTICS | UNITED STATES | $954.2K | 40 |
| LIFESCIENCE LOGISTICS. | UNITED STATES | $265.0K | 17 |
| MEDICINS SANS FRONTIERES LOGISTIQUE | FRANCE | $39.1K | 4 |
| COSPHARM PHARMACEUTICALS PRIVATE LIMITED | ZIMBABWE | $22.3K | 1 |
| COSPHARM PHARMACEUTICALS PVT LTD | ZIMBABWE | $21.8K | 3 |
India exported $19.0M worth of Erythromycin through 3,939 shipments from 368 suppliers to 135 countries, serving 992 buyers globally. Cadila Pharmaceuticals Limited contributes $1.4M to this total, accounting for 1.8% of India's Erythromycin exports. Cadila Pharmaceuticals Limited ships Erythromycin to 5 countries through 9 buyers.
Cadila Pharmaceuticals Limited's average Erythromycin shipment value is $20.8K per consignment, based on 69 shipments totaling $1.4M. The largest destination is UNITED STATES (91.5% of Cadila Pharmaceuticals Limited's Erythromycin exports).
Cadila Pharmaceuticals Limited ranks #6 among 368 Indian Erythromycin exporters with a 1.8% market share. The top 3 exporters are MEDOPHARM ($3.0M), S KANT HEALTHCARE LIMITED ($2.8M), MEDREICH LIMITED ($2.1M). Cadila Pharmaceuticals Limited processed 69 shipments to 5 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PHARMACEUTICALS MEDICINES: ERYTHROMYCIN | $219.8K | 7 |
| PHARMACEUTICALS MEDICINES:ERYTHROMYCIN T | $175.3K | 5 |
| PHARMACEUTICALS MEDICINES:ERYTHROMYCIN O | $63.6K | 4 |
| PHARMAEUTICALS MEDICINES: ERYTHROMYCIN TABLETS USP 250 MG-100 TAB | $62.9K | 2 |
| PHARMAEUTICALS MEDICINES:ERYTHROMYCIN OR | $55.5K | 3 |
| ERYTHROMYCIN TABLETS USP 250MG (ERYTHROMYCIN 250MG TABLETS) (R/M:ERYTHROMYCIN BASE USP) [24384 PACK X 1X30= 731520 NOS] | $50.0K | 1 |
| PHARMA MEDIC:ERYTHROMYCIN ORAL SUSPENSIO | $48.6K | 1 |
| ERYTHROMYCIN TABLETS USP 250MG (ERYTHROMYCIN 250MG TABLETS) (R/M:ERYTHROMYCIN BASE USP) [9984 PACK X 1 X 30=299520 NOS] | $47.4K | 3 |
What Cadila Pharmaceuticals Limited must comply with to export Erythromycin to its top destination countries
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
Exporters ranked immediately above and below #6 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 4 | S KANT HEALTHCARE LIMITED | $2.8M | 94 | 20 | $29.9K |
| 5 | MEDREICH LIMITED | $2.1M | 96 | 4 | $22.1K |
| 6 | CADILA PHARMACEUTICALS LIMITED ★ | $1.4M | 69 | 5 | $20.8K |
| 7 | BHARAT PARENTERALS LIMITED | $1.4M | 37 |
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 513 | 13.0% |
| DELHI AIR CARGO ACC (INDEL4) | 394 | 10.0% |
| SAHAR AIR | 377 | 9.6% |
| NHAVA SHEVA SEA (INNSA1) | 370 | 9.4% |
| JNPT/ NHAVA SHEVA SEA | 234 | 5.9% |
| DELHI AIR | 227 | 5.8% |
| JNPT | 176 | 4.5% |
| Bombay Air | 99 | 2.5% |
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Cadila Pharmaceuticals. The ongoing Israel-Iran tensions have led to disruptions in the Red Sea shipping routes, causing major carriers to suspend or reroute transits. This has resulted in extended transit times by 10–20 days and increased freight rates by 40–50% on key India–Europe routes, impacting the timely delivery of pharmaceuticals. (livemint.com)
Conversely, the U.S.-China trade tensions have prompted the United States to diversify its pharmaceutical supply chain, creating opportunities for Indian exporters. However, the U.S. has also implemented tariffs on Active Pharmaceutical Ingredients (APIs), leading to a reshoring of manufacturing and affecting Indian firms. In response, some Indian companies have invested in U.S. facilities to circumvent these tariffs. (odrindia.in)
In the European Union, compliance with the Falsified Medicines Directive (FMD) has become imperative. Indian exporters must ensure stringent adherence to these regulations to maintain market access, necessitating investments in serialization and traceability systems.
Compliance with international regulatory standards is crucial for Indian pharmaceutical exporters. The U.S. Food and Drug Administration (FDA) has previously issued warnings to Cadila Pharmaceuticals regarding deviations from standard manufacturing practices. (business-standard.com) To address such concerns, the company has invested in enhancing its quality control systems and manufacturing processes. Additionally, Cadila has engaged in legal proceedings concerning biosimilar approvals, highlighting the complexities of regulatory compliance in the biosimilars market. (legaleraonline.com)
Cadila Pharmaceuticals Limited exports 15 products worth $20.2M. Beyond Erythromycin, top products include Mebendazole, Verapamil, Folic, Domperidone, Ethambutol. View the complete Cadila Pharmaceuticals Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Erythromycin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cadila Pharmaceuticals Limited's Erythromycin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cadila Pharmaceuticals Limited
Full Company Profile →
15 products · $20.2M total trade · 11 categories
| UNITED STATES |
| $17.0K |
| 1 |
| MSF SUPPLY C/O DSV AIR AND SEA NV | BELGIUM | $11.9K | 1 |
| NEW VISION DISTRIBUTORS LTD | JAMAICA | $10.5K | 2 |
| MEDICINS SANS FRONTIERS LOGISTIQUE | FRANCE | $8.5K | 1 |
Cadila Pharmaceuticals Limited supplies Erythromycin to 9 buyers globally. The largest buyer is LIFESCIENCE LOGISTICS (UNITED STATES), followed by LIFESCIENCE LOGISTICS. (UNITED STATES) and MEDICINS SANS FRONTIERES LOGISTIQUE (FRANCE). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
| ERYTHROMYCIN TABLETS USP 500 MG-30 TAB ( | $38.1K | 1 |
| PHARMAEUTICALS MEDICINES: ERYTHROMYCIN TABLETS USP 500 MG-30 TAB (3648X1X30T) (R/M :ERYTHROMYCIN BASE USP 500 MG)NOS | $32.5K | 3 |
Cadila Pharmaceuticals Limited exports 38 distinct Erythromycin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHARMACEUTICALS MEDICINES: ERYTHROMYCIN with 7 shipments worth $219.8K.
| 2 |
| $36.6K |
| 9 | BIOMATRIX HEALTHCARE PRIVATE LIMITED | $1.3M | 46 | 4 | $28.0K |
Cadila Pharmaceuticals Limited ranks #6 among 368 Indian Erythromycin exporters. Average shipment value of $20.8K compared to the market average of $51.7K. The closest competitors by value are S KANT HEALTHCARE LIMITED and MEDREICH LIMITED.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 135+ countries, 992+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Cadila Pharmaceuticals Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Erythromycin. For current shipment-level data, contact TransData Nexus.